Neurogene (NASDAQ: NGNE) — Company Overview, News & Financial Data
Neurogene develops gene therapy treatments for nervous system disorders utilizing AAV vectors for targeted delivery.
Neurogene
Neurogene (NASDAQ:NGNE) is a biotechnology company developing gene therapy treatments for nervous system disorders. They utilize adeno-associated virus (AAV) vectors to deliver corrective genetic material to target cells, potentially offering a new approach to treating neurological conditions. Neurogene's pipeline might focus on treatments for rare or debilitating diseases with limited therapeutic options. While they are still in the pre-commercial stages, with clinical trials ongoing, Neurogene's gene therapy research holds promise for offering life-changing treatments for patients with neurological conditions.
Snapshot
Operations
Products and/or services of Neurogene
- Adeno-associated virus (AAV) based gene therapy for neurological diseases, aiming to address genetic disorders by delivering normal genes to patients' cells.
- Development of a gene therapy for Aspartylglucosaminuria (AGU), a rare lysosomal storage disease, focusing on reducing the accumulation of glycoasparagines.
- Gene therapy targeting Charcot-Marie-Tooth Disease, specifically focusing on mutations in the GJB1 gene, aiming to restore normal nerve function.
- Exploration of therapies for Rett Syndrome, a neurodevelopmental disorder, focusing on correcting MECP2 gene mutations.
- Next-generation sequencing (NGS) diagnostics for early identification of rare neurological genetic disorders, enabling timely intervention.
- Engagement in educational initiatives for the broader community about rare neurological genetic disorders, aiming to raise awareness and support affected families.
Neurogene executive team
- Rachel L. McMinnFounder, Executive Chair & CEO
- Christine Mikail CvijicPresident, CFO & Director
- Julie JordanChief Medical Officer
- Stuart CobbChief Scientific Officer
- Lina LiExecutive Director of Investor Relations
- Donna M. Cochener-MetcalfeSenior VP, General Counsel & Corporate Secretary
- Andrew E. MulbergSenior VP of Regulatory Affairs, Quality Assurance & Quality Control
- Ricardo JimenezSenior Vice President of Technical Operations
- Arvind SreedharanSenior Vice President of Business Operations
- Christina ShaferChief Commercial Officer
Key financials
Reported results for Neurogene, in USD.
- Market cap
- 576.7M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -5.0
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -103.2M | -90.4M | |
| 925K | -82.6M | -75.1M | |
| 0 | -55.6M | -36.3M | |
| 0 | -56.5M | -55.2M |